Global Vision HK

Global Vision HK Global Vision HongKong Limited
高視遠望香港有限公司

11/06/2020
11/06/2020
New A/B/S UBM Ultrasound Platform
10/06/2020

New A/B/S UBM Ultrasound Platform

Product of our partners
10/02/2018

Product of our partners

Welcome to join us at APAO 2018, booth 3E-25.
10/02/2018

Welcome to join us at APAO 2018, booth 3E-25.

APAO 2018, Hong KongProgram Overview
08/02/2018

APAO 2018, Hong Kong
Program Overview

2018 APAO, Hong KongGaush, Global VisionBooth no.: 3E-25Partners: HEIDELBERG, ROLAND CONSULT, Geuder, SCHWIND, OPTOS, Ph...
08/02/2018

2018 APAO, Hong Kong
Gaush, Global Vision
Booth no.: 3E-25

Partners: HEIDELBERG, ROLAND CONSULT, Geuder, SCHWIND, OPTOS, Phoenix, Espansione

EYESI by VRmagic, is now available.-Taking the Patient Out of the Surgical Learning Loop-Lifelike Training Environment f...
10/01/2018

EYESI by VRmagic, is now available.

-Taking the Patient Out of the Surgical Learning Loop
-Lifelike Training Environment for Optimal Practice
-Immediate Feedback after each Task
-Monitoring Skill Development Over Time
-Less Complications in Intraocular Surgery
-Highly Realistic Training Experience
-Unlimited Independent Practice
-Competency-Based Assessment
-Online Teaching Solution with VRmNet

Eye Light is now available.-Two Unique technologies: Meibomian Gland’s Direct and Indirect treatment -Patented technolog...
10/01/2018

Eye Light is now available.

-Two Unique technologies: Meibomian Gland’s Direct and Indirect treatment
-Patented technologies used in medicine and surgery
-Only few minutes: 3’ OPE® + 15’ Light Modulation®
-Software sets parameters: completely automatic

EYE TECH CARE is now available.-Unique technology for non-invasive treatment -Pioneering strategy -Straightforward, easy...
10/01/2018

EYE TECH CARE is now available.

-Unique technology for non-invasive treatment
-Pioneering strategy
-Straightforward, easy set-up and rapid treatment procedure
-An exclusive medical device

DIOPSYS is now available.-Gain objective, functional information about retinal ganglion cells to help with early detecti...
10/01/2018

DIOPSYS is now available.

-Gain objective, functional information about retinal ganglion cells to help with early detection
-Objectively measure functional loss from retinopathies, even through the presence of cataracts
-Enhance your functional evaluation with objective information on the entire visual pathway
-Collect objective, functional data from your pediatric patients’ the entire visual pathway

New study proves advantages of MultiColor imaging over fundus photography for early diagnosis and monitoring of AMDHeide...
13/10/2017

New study proves advantages of MultiColor imaging over fundus photography for early diagnosis and monitoring of AMD

Heidelberg, Germany – A research group from the Centre for Public Health at the Queen’s University in Belfast, Northern Ireland, has just published the results of a study comparing SPECTRALIS® MultiColor imaging and traditional color fundus photography for the detection of features of early and late age-related macular degeneration (AMD). The study’s findings demonstrate the benefits of SPECTRALIS MultiColor imaging for increased sensitivity and specificity.

The SPECTRALIS MultiColor Module is an imaging modality which utilizes confocal scanning laser technology instead of white light to visualize the retina.
The SPECTRALIS MultiColor Module is an imaging modality which utilizes confocal scanning laser technology instead of white light to visualize the retina.
The study, which was published digitally in August and will appear in the November issue of Retina, is titled: “Identifying features of early and late AMD: A comparison of MultiColor versus traditional color fundus photography”. The authors are Katie W. Graham, Usha Chakravarthy, Ruth E. Hogg, K. Alyson Muldrew, Ian S. Young and Frank Kee, all of the Centre for Public Health, Queen’s University in Belfast, Northern Ireland.
The goal of the study was to compare the MultiColor Module of the SPECTRALIS diagnostic imaging platform to color fundus photography (CFP), which is currently considered the gold standard examination for the recognition and classification of features of early and late AMD. The SPECTRALIS MultiColor Module, on the other hand, is a newer imaging modality which utilizes confocal scanning laser technology with light of discrete wavelengths instead of standard optics and white light to visualize the retina.

MultiColor was proven to have higher sensitivity than CFP for the detection of early AMD features using a sample of 105 eyes. In cases with discrepancies, an analysis of OCT also showed better agreement with MultiColor for all AMD lesions, with the exception of hemorrhage and non-geographic atrophy hypopigmentation. For pigment clumping, CFP and MultiColor were in equal agreement to OCT.

MultiColor imaging was able to identify soft drusen in 85%, reticular drusen in 83%, and atrophy and fibrosis in 100% of cases where these abnormalities were seen on CFP. However, when using MultiColor as the basis for analysis, CFP was less sensitive. In this analysis, soft drusen were identified in only 58%, reticular drusen in 28%, atrophy in 83%, and fibrosis in 68% of the cases where such changes were seen on MultiColor images.

“This systematic analysis of color fundus photography versus MultiColor demonstrated the robustness of MultiColor imaging in the detection of early AMD features. The ability to delineate atrophy and fibrosis in late stage AMD gives added value in the clinical setting, as these components of the wet AMD lesion have an important impact on visual function”, said Usha Chakravarthy, Professor of Ophthalmology and Vision Sciences at Queen’s University, Belfast, Northern Ireland.

Other clinicians also familiar with the MultiColor Module appreciate its advantages: “With the advent of MultiColor imaging we can obtain high-resolution fundus images for a precise study of the morphometric changes of the retina and combine them with structural OCT scans of up to 55 degrees. This gives us the possibility to monitor changes from visit to visit in both imaging modalities. In addition, at our clinic we can even obtain an OCTA over a MultiColor image, selecting the area of particular interest. And all of that, without having the patient moving from one system to another”, said Roberto Gallego-Pinazo, MD, Retina Specialist of the Macula Unit at Oftalvist in Valencia, Spain.

See structure at different depths

MultiColor is able to achieve such sensitivity and specificity due to its confocal scanning laser imaging technology, which uses three laser wavelengths (blue, green and infrared) simultaneously to provide diagnostic images that show distinct structures at different depths within the retina. As a result, the high-resolution MultiColor images can be used to detect and delineate structures and pathologies not visible on ophthalmoscopy and fundus photography.

MultiColor images can and should ideally be visualized both as a composite image combining all three wavelengths and also as individual blue, green and infrared reflectance images. Each of the three reflectance images offers unique details due to the pe*******on depth and reflectance properties of each individual wavelength used. The infrared reflectance image shows deeper structures in the choroid and the retinal pigment epithelium. The green reflectance image is useful for examining blood, blood vessels, and exudates. The blue reflectance image is best for identifying changes in superficial retinal structures, like epiretinal membranes or retinal nerve fiber layer defects.

MultiColor as part of a multimodal approach
“It is encouraging to see the clinical significance of the MultiColor Module proven in a large study related to a prevalent pathology such as AMD. Beyond the clinical value, clinicians also appreciate the fact that MultiColor images can be acquired through undilated pupils and in patients with media opacity or even nystagmus. While we don’t see MultiColor as a substitute for color fundus photography, which remains useful for documentation purposes, it is a particularly useful diagnostic tool that can be combined with other imaging modalities”, said Dr. Kester Nahen, Managing Director at Heidelberg Engineering.

South China Morning Post
08/09/2017

South China Morning Post

A study by the Chinese University of Hong Kong will use 100 people to test new methods of detecting Alzheimer’s disease, which if successful will be cheaper and more accessible

星島日報報道
08/09/2017

星島日報報道

  (星島日報報道)香港中文大學醫學院與養和醫院合作展開「早期阿茲海默症篩查研究」,昨起招募一百位公眾人士參與,以不具入侵性的視網膜影像技術,判斷研究對象患上阿茲海默症的風險,以及早診斷早期的老人認知障礙症患者。  中大醫學院內科及藥物治療學系腦神經科主任莫仲棠表示,現時認知...

中文大學新聞發布
08/09/2017

中文大學新聞發布

東方日報報訊
08/09/2017

東方日報報訊

【本報訊】要確診是否患腦退化,將來未必要靠腦部掃描,簡單的眼睛檢查即可診斷。俗稱腦退化症的阿茲海默症若能於發病初期治療,有助控制病情,但現時篩查方法具入侵性,大多數患者不會接受檢測,任由病情繼續惡化。中文大學與養和醫院合作,進行全球首個利用視網膜影像篩查阿茲海默症的研究,估計準確率達到八成,低成本檢測有望令篩查普及化。

大公報報訊
08/09/2017

大公報報訊

大公網

明報專訊
08/09/2017

明報專訊

【明報專訊】眼睛被視為「靈魂之窗」,亦是中樞神經系統的延伸,可成為觀察腦部退化情况的「窗口」。中大醫學院正展開「早期阿兹海默症篩查研究」,盼兩年內為100名參加者做檢查,探討以「視網膜影像」作阿茲海默症篩查的準確度。若研究成功,將有助及早篩查出早期患者並及早介入治療。

科技日新月異,醫學理念不斷更新唯有不斷超越,才能鑄就傳奇!
29/06/2017

科技日新月異,醫學理念不斷更新
唯有不斷超越,才能鑄就傳奇!

29/06/2017

AMARIS 1050RS中國上市會

2017年5月18日 上海
全國角膜病會開幕在即
中國眼科屈光領域又喜迎載入史冊的一刻:
全球准分子激光領導者
AMARIS產品家族最新成員
AMARIS 1050RS
中國盛大上市

眼底出現 Angioid streaks(血管樣條紋),如何診斷和治療?Angioid streaks (血管樣條紋) 與Bruch′s膜鈣化破裂有關,在不同的影像模式下會顯示不同的影像特點。假如沒有累及黃斑出現CNV等病變,病人往往因視力...
28/06/2017

眼底出現 Angioid streaks(血管樣條紋),如何診斷和治療?

Angioid streaks (血管樣條紋) 與Bruch′s膜鈣化破裂有關,在不同的影像模式下會顯示不同的影像特點。假如沒有累及黃斑出現CNV等病變,病人往往因視力很好不易察覺。但是,一旦出現CNV,常常導致黃斑區的瘢痕化,盡管已有anti-VEGF和PDT等技術,治療起來仍頗為棘手。

眼底"Angioid streaks"的治療

當“Angioid streaks”出現CNV時,目前的治療主要手段是anti-VEGF和PDT技術,但是,相對其它的CNV,血管樣條紋CNV似乎表現出更為明顯的疤痕化傾向,因此在治療效果方面顯得十分棘手。

Angioid streaks's CNV的治療,採取“多靶點”方案可能會更好一些。在這方面,中醫治療的介入可能會成為未來治療的一個方向。尤其是,當發現了Angioid streaks但並未出現CNV時,中醫方法或更能發揮它的優勢。

21/06/2017

Fantastic launch event in Shanghai, hosted by our parent comapny "Global Vision Limited", Let's watch it!!!

FAF+OCT跟進視網膜色素病變(Retinitis Pigmentosa)兩年,發現了什麼?視網膜色素病變(Retinitis Pigmentosa,RP)是一種涉及光感受器(photoreceptors,PR)細胞的緩慢進展的疾病,早期...
16/06/2017

FAF+OCT跟進視網膜色素病變(Retinitis Pigmentosa)兩年,發現了什麼?

視網膜色素病變(Retinitis Pigmentosa,RP)是一種涉及光感受器(photoreceptors,PR)細胞的緩慢進展的疾病,早期涉及周邊網膜,晚期損害中央視力。既往多個研究表明,多模式成像聯合應用,可以更準確的評估RP的眼底狀態。

本研究應用Heidelberg Spectralis HRA+OCT一體機測量高(fundus autofluorescence, FAF)的水平直徑和垂直直徑,橢圓體帶寬度,對71個例子視網膜色素病變(RP)患者進行無創的影像學,通過OCT和AF影像比較來確定晚期視網膜色素病變(RP)的進展速度和最佳跟進時間。研究發現:

1、在兩年跟進期間,約75%的患者觀測到明顯的進展,橢圓體帶寬度、高FAF水平和垂直直徑的年平均進展率分別為 0.45° (4.9%)、 0.51° (4.1%)和 0.42° (4.0%)。
2、橢圓體帶寬度、高FAF水平和垂直直徑測量變異度較小,分別為8.9%, 9.5% 和9.6%。
3、本研究第一次證明左右眼進展速度的非對稱性(19%的患者)。越接近黃斑中心凹,進展越慢。
4、進展速度跟患者年齡,性別,遺傳性疾病的種類沒有顯著相關性。

綜上所述,FAF 和Spectralis OCT在跟進視網膜色素病變(Retinitis Pigmentosa,RP)患者的進展中測量數據可靠精準,相關性強,可與功能評估一起作為進一步治療的評估指標。間隔一年的跟進足以有效地監測進展。

Heidelberg Spectralis HRA+OCT 一體機可以通過FAF 和Spectralis OCT測量幫助臨床醫生無創跟進RP患者的進展。豐富的成像模式,根據疾病選擇合適的影像手段,Heidelberg與眼科醫生一起為廣大病患提供精準診療!

Address

Unit 1202, 12/F, Pilkem Commercial Centre, 8 Pilkem Street
Jordan

Alerts

Be the first to know and let us send you an email when Global Vision HK posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Videos

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Other Jordan clinics

Show All